The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...

Sarepta stock crashed Friday — wiping out almost all of the gains tied to its restructuring plans — after a third recipient of one of its gene therapies died.According to analysts and several media ...

A company spokesperson told Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage ...